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PIN49
HOW DOES PATIENT REPORT OF SYMPTOM
IMPACT RELATE TO CLINICAL FUNCTIONING
IN CHRONIC BRONCHITIS?
Frank L1, Margolis MK1, Barker C1, Duprat-Lomon I2,
Amiot N2, Sagnier PP3
1MEDTAP International, Bethesda, MD, USA; 2Bayer Pharma,
Puteaux, France; 3Bayer plc, Slough, United Kingdom
OBJECTIVES: The Acute Bronchitis Symptom Severity
(ABSS) Scale is a new 7-item, 5-point Likert-scaled patient
reported outcomes instrument designed to capture symp-
toms of acute exacerbations of chronic bronchitis (AECB)
and their impact on functioning. In a multi-site interna-
tional randomized controlled trial comparing a 5-day oral
moxiﬂoxacin (MXF) course to that of a 7-day standard
oral antibiotic regimen (amoxicillin, clarithromycin, 
or cefuroxime-axetil) in the treatment of AECB (the
MOSAIC trial), the ABSS demonstrated good psychome-
tric properties and the ability to detect clinically mean-
ingful change over time. Higher ABSS scores indicate
poorer clinical status. A score drop of 0.7 point (18% of
scale score) is associated with clinical improvement as
rated by the clinician. The contribution of speciﬁc clini-
cal factors to ABSS score is not yet known, however.
METHODS: To assess the contribution of clinical factors
to ABSS score during an exacerbation episode, a multi-
variable ordinary least squares regression equation was
analyzed and the contribution of each variable to overall
adjusted R2 was evaluated. Indicators of chronic bron-
chitis severity used as independent variables were age
(</≥65 years), gender, use of either long-term inhaled
steroids or systemic steroids during the study period with
no change in dose regimen for acute episode (yes/no),
duration of chronic bronchitis (</≥15 years), number of
exacerbations in prior year (</≥4), and baseline FEV1
(</≥50% predicted); ABSS score the dependent variable.
RESULTS: Adjusted model R2 was 0.068. FEV1 con-
tributes approximately 40% of total R2 (p < 0.01) fol-
lowed by use of steroids (p < 0.01) and female gender 
(p < 0.01), which both relate to ABSS score. CONCLU-
SIONS: Results support a relationship between an 
objective measure of lung function and patient report
about bronchitis symptoms and their impact on daily
activities.
PIN50
VALIDATION OF THE HEALTH RELATED
PRODUCTIVITY QUESTIONNAIRE DIARY
(HRPQ-D) ON A SAMPLE OF PATIENTS WITH
INFECTIOUS MONONUCLEOSIS: RESULTS
FROM AN OBSERVATIONAL STUDY
Kumar RN1, Hass SL2, Li JZ2
1University of Michigan, Ann Arbor, MI, USA; 2Pharmacia
Corporation, Kalamazoo, MI, USA
OBJECTIVE: Assess the performance of the newly devel-
oped Health Related Productivity Questionnaire-Diary
(HRPQ-D). METHODS: A multi-center observational
clinical study on patients suffering from infectious
mononucleosis was conducted between January and
April, 2001. Patients completed the HRPQ-D daily for
one-week periods during weeks 1, 2, 4, and 8. Weekly
productivity loss was measured as absenteeism (sum of
the number of hours missed), presenteesim (productivity
decreases due to reduced effectiveness), and combined
lost productivity (absenteeism plus presenteeism) for
three work venues (work outside home, housework, and
classes/homework). Validation was conducted by corre-
lating the productivity measures with the patient-reported
severity of seven symptoms. The responsiveness of the
HRPQ-D was also assessed by correlating the change in
productivity scores and the change in symptom severity
scores between study weeks. RESULTS: A total of 42
patients were enrolled in the study. Symptom scores 
were positively correlated with lost work hours due to
absenteeism and combined lost productivity scores. The
symptom score had a strong correlation with the com-
bined lost productivity across all venues (r = 0.577),
which was mainly driven by the symptom score’s strong
correlation with absenteeism across all venues (r = 0.680).
Perhaps owing to the age groups affected by infectious
mononucleosis, school productivity was particularly well
correlated with symptom severity. Statistically signiﬁcant
correlations to symptom scores were observed in weeks
2 and 4 for school absenteeism (r = 0.438 and r = 0.531,
respectively). The signiﬁcant correlation values between
the change in symptom scores and change in productiv-
ity scores for all week combinations ranged from a low
of -0.161 for presenteeism across all venues to a high 
of 0.422 for school absenteeism. CONCLUSIONS:
The HRPQ-D demonstrated good construct validity and
responsiveness, making it a useful tool for determining
productivity levels across different work venues within
clinical trial or survey research applications.
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ASSESSING DISEASE-SPECIFIC UTILITY IN
RECURRENT GENITAL HERPES (RGH)
Doward LC1, McKenna SP1, Meads DM1, Ratcliffe J2,
Langley PC3
1Galen Research, Manchester, United Kingdom; 2Research
Triangle Institute, Manchester, UK; 33M Pharmaceuticals, St
Paul, MN, USA
OBJECTIVES: Utility calculation generally relies on the
use of generic measures that assess health status. Evidence
suggests that such measures have limited responsive-
ness—largely because the health states described are of
limited relevance to any speciﬁc disease. Quality of life
(QoL) assessment has shown that it is not health status
itself that is important to patients but the impact that this
might have on their lives. Consequently, it would appear
more appropriate for utility to be determined by prefer-
ence for different QoL states, particularly in Quality
Adjusted Life Year (QALY) type analyses. The present
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study was designed to determine QoL-based utilities 
speciﬁc to RGH. METHODS: Discrete choice conjoint
analysis (CA) and time trade off (TTO) exercises were
conducted using QoL states generated from six items
from the RGH Quality of Life Questionnaire (RGHQoL).
RGH patients completed tasks via interview. RESULTS:
One hundred ninety-two interviews were conducted (79
male, 113 female; age range 19–69 years, mean age 38.4).
For CA, all attributes were statistically signiﬁcantly inﬂu-
ential in determining preferences. The application of the
random effects probit model produced coefﬁcient values
that can be used as preference weights. For the TTO exer-
cise, coefﬁcient values (preference weights) were derived
by application of the random effects tobit regression
model. These coefﬁcient values can be used to derive rel-
ative and absolute utility values respectively. As the TTO
technique possesses cardinal properties, QALY scores 
can also be calculated. CONCLUSIONS: It is feasible to
generate both relative and absolute utility values from
responses to the RGHQoL questionnaire, allowing utility
to be based on true QoL. The ability to derive disease-
speciﬁc QoL-based utilities in this way means that the
same instrument can be used to generate both QoL and
utility data from the same clinical trial.
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GALANTAMINE REDUCES CAREGIVER TIME:
AN ANALYSIS OF A NATIONAL SAMPLE 
OF ALZHEIMER’S PATIENTS LIVING IN 
THE COMMUNITY
Meletiche D1, Bolge SC2, Small GW3
1Janssen Pharmaceutica,Titusville, NJ, USA; 2Consumer Health
Sciences, Princeton, NJ, USA; 3UCLA Center for Aging,
Neuropsychiatric Institute, Los Angeles, CA, USA
OBJECTIVE: Patients with Alzheimer’s disease (AD)
have progressive cognitive, functional, and behavioral
decline, resulting in increased reliance on caregivers for
assistance with activities of daily living. Galantamine, a
novel treatment for AD with a dual mode of action
(acetylcholinesterase inhibition and allosteric nicotinic
receptor modulation), has demonstrated beneﬁts on cog-
nition, global function, activities of daily living, and
behavioral symptoms in patients with mild-to-moderate
AD. The objective of this study was to determine differ-
ences in caregiving time between caregivers of AD
patients receiving galantamine and those receiving no
treatment. METHODS: The analysis was based on data
from the AD Caregiver Project survey. Data were col-
lected using a self-administered questionnaire distributed
in December 2001 to a large national sample of unpaid
caregivers. Caregiver time was deﬁned as the number of
hours spent by the primary caregiver during a typical
week. Only patients living in the community were
included in the analysis. Using linear regression, caregiv-
ing times for galantamine-treated and untreated patients
were compared. Covariates included patient and care-
giver demographics, including employment status and
income level, and patient disease severity, functional
status, and living situation. RESULTS: Galantamine
patients (N = 97) differed from untreated patients (N =
803) with regard to gender (61% vs 35% males), age
(74.1 vs 79.6 years), and living situation (1% vs 6%
living alone). Caregivers of galantamine patients were
older (66.3 vs 59.2 years) and more likely to be a spouse
(77% vs 33%). After controlling for differences between
the groups, caregivers of galantamine patients provided
18 fewer hours of care per week than caregivers 
of untreated patients (95% CI: 3.3–32.5, p = 0.016).
CONCLUSION: Compared with untreated patients,
patients treated with galantamine appear to require sig-
niﬁcantly less caregiving time.
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IMPACT OF RIVASTIGMINE ON TIME TO FIRST
ANTIPSYCHOTIC DRUG USE IN PATIENTS
WITH ALZHEIMER’S DISEASE
Suh DC1,Arcona S2,Thomas S2, Chang S2, Powers C1
1Rutgers University, Piscataway, NJ, USA; 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVE: To investigate the effect of rivastigmine
treatment on the time to ﬁrst antipsychotic drug use
among patients with Alzheimer’s disease (AD), compared
to patients not treated with a cholinesterase inhibitor
(ChEI). METHODS: This study used MarketScan®
research databases from January 1, 1999 through Decem-
ber 31, 2001. Patient inclusion criteria included: (a) diag-
nosis of AD, (b) ≥65 years old at diagnosis, and (c)
continuous insurance coverage. Patients who previously
used any antipsychotics were excluded. Subjects were
classiﬁed into a ChEI group with the ﬁrst prescription
date as the index date or a non-ChEI group. Patients on
rivastigmine were further identiﬁed from the ChEI group.
Chi-square test, t-test, and log-rank test were used to test
differences in study variables between groups. Cox pro-
portional hazard models were used to estimate predicted
risk of the ﬁrst antipsychotic drug use. RESULTS: A total
of 2391 patients were included in the study (996 ChEI
and 1395 non-ChEI). ChEI users were younger compared
to non-ChEI users (79 vs. 81 years, P < 0.0001). However,
there were no signiﬁcant differences between antipsy-
chotic users and non-users, by age or gender. Over the
entire observation period, Kaplan-Meier analysis indi-
cated that users of ChEIs were 4% (relative risk (RR) =
0.96; 95% CI:0.77–1.18) less likely and patients taking
rivastigmine speciﬁcally (N = 214) were 19% (RR = 0.81;
95% CI:0.54–1.21) less likely to take antipsychotics as
compared to patients not taking ChEIs. After controlling
for demographic covariates, use of other psychotropics
and anticonvulsants, rivastigmine patients were 34% (RR
= 0.66; 95% CI:0.36–1.22) less likely to take antipsy-
